Cargando…
Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
BACKGROUND & OBJECTIVES: Vaccination against SARS-CoV-2 is a recommendation from the World Health Organization as the foremost preference in the current situation to control the COVID-19 pandemic. BBV152 is one of the approved vaccines against SARS-CoV-2 in India. In this study, we determined SA...
Autores principales: | Kumar, Nathella Pavan, Padmapriyadarsini, C., Uma Devi, K. R., Banurekha, V. V., Nancy, Arul, Girish Kumar, C. P., Murhekar, Manoj V., Gupta, Nivedita, Panda, Samiran, Babu, Subash, Bhargava, Balram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555618/ https://www.ncbi.nlm.nih.gov/pubmed/34528524 http://dx.doi.org/10.4103/ijmr.IJMR_2066_21 |
Ejemplares similares
-
Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses
por: Kumar, Nathella Pavan, et al.
Publicado: (2021) -
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021) -
Effect of BCG vaccination on proinflammatory responses in elderly individuals
por: Pavan Kumar, Nathella, et al.
Publicado: (2021) -
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021) -
Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis
por: Kumar, Nathella Pavan, et al.
Publicado: (2016)